Rick Weissenstein

Managing Director, Washington Research Group - Health Care Services & Pharmaceutical Policy

Headshot photo of Rick Weissenstein

Rick Weissenstein joined TD Cowen Washington Research Group in August 2016 and covers health care services policy issues. TD Cowen Washington Research Group was recently named #1 in the Institutional Investor Washington Strategy category.  The team has been consistently ranked among the top macro policy teams for the past decade. Previously he worked as a senior analyst at Guggenheim Securities, MF Global, Stanford Financial, and Schwab Soundview, where he was responsible for analyzing health care policy issues and emerging trends in the federal and state legislative, regulatory, and legal arenas and their implications for the health care industry.

He was formerly the Washington Bureau Chief for Modern Healthcare magazine, and a reporter for Advertising Age magazine. Mr. Weissenstein began his career as a Certified Public Accountant in the Chicago office of Ernst & Young. He earned a bachelor’s degree in accounting at Millikin University, and a master’s degree in journalism at the University of Illinois, Champaign-Urbana.

Material prepared by the TD Cowen Washington Research Group is intended as commentary on political, economic, or market conditions and is not intended as a research report as defined by applicable regulation.

Get In Touch

Start a conversation with Rick Weissenstein

    Insights

    Explore related thought leadership, reports, coverage and insights for Rick Weissenstein.

    A chemist in a lab is taking precaution as he conducts research in full protective gear towards the end of biodefense.
    Ahead of the Curve®

    A New Chapter In Biosecurity: Are We Prepared?

    Pharmacist pulls out medicine from pull out white drawer.
    Ahead of the Curve®

    Will GLP-1s Eat The World?

    A doctor in scrubs is seated next to a man in a suit in sun lit conference room. Both are addressing the rest of the group out of frame with a graph behind them.
    Ahead of the Curve®

    Where’s The Money?: State Of Federal Biomedical Funding